Tenaya Therapeutics (NASDAQ:TNYA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Tenaya Therapeutics (NASDAQ:TNYA) from a strong sell rating to a sell rating in a research note issued to investors on Sunday morning,Wall Street Zen reports.

Separately, Weiss Ratings upgraded Tenaya Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Tenaya Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $4.00.

Tenaya Therapeutics Trading Down 2.9%

Shares of NASDAQ:TNYA opened at $0.66 on Friday. The company has a market capitalization of $148.75 million, a price-to-earnings ratio of -1.25 and a beta of 2.77. Tenaya Therapeutics has a 12 month low of $0.53 and a 12 month high of $2.35. The firm’s 50-day moving average is $0.76 and its 200 day moving average is $0.75.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.13). The company had revenue of $1.11 million for the quarter, compared to the consensus estimate of $10.00 million. As a group, equities analysts forecast that Tenaya Therapeutics will post -0.38 EPS for the current fiscal year.

Institutional Investors Weigh In On Tenaya Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Spark Investment Management LLC bought a new position in Tenaya Therapeutics in the 2nd quarter worth about $26,000. Integrity Wealth Solutions LLC bought a new stake in shares of Tenaya Therapeutics during the first quarter valued at approximately $27,000. Scientech Research LLC purchased a new stake in shares of Tenaya Therapeutics in the third quarter valued at approximately $27,000. Callan Family Office LLC purchased a new stake in shares of Tenaya Therapeutics in the second quarter valued at approximately $37,000. Finally, Comerica Bank bought a new position in Tenaya Therapeutics in the first quarter worth approximately $50,000. 90.54% of the stock is owned by hedge funds and other institutional investors.

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.